# Continuing Education Activity

The six-minute walk test is a simple cardiopulmonary functional testing modality. Its straightforward nature allows for a non-specific, integrated assessment of the many systems involved during physical activity. Specifically, its results can assist in ascertaining the degree of functional impairment and potentially lead to modifications in therapy for some cardiovascular and pulmonary conditions. This activity reviews the six-minute walking test, its physiological basis, uses in practice, and outlines the role of the healthcare team in its performance.

**Objectives:**
- Review the preparation, equipment, personnel, and technique used in performing the six-minute walk test.
- Identify the indications and contraindications of the six-minute walk test.
- Outline the clinical uses of the six-minute walk test.
- Describe relevant interprofessional aspects of the test to improve patient outcomes.

# Introduction

There are a number of field walking tests designed to measure the exercise capacity of patients with chronic respiratory disease. Among these, the 6-minute walk test (6MWT) is a key study providing a functional, therapeutic response, and prognostic data that is valuable in the care of patients with respiratory as well as cardiac diseases. It is used widely due to its simplicity and reproducibility, delivering a consolidated image of the cardiopulmonary and musculoskeletal response to exercise. It requires no special training on the part of the staff performing it, items and equipment available at any clinician's office or hospital may be used, and is safe and well-tolerated by most patients at any stage of disease, with the test being highly reflective of usual daily activity and exercise performance.

It is particularly useful in assessing and monitoring chronic obstructive pulmonary disease (COPD) and has a role in managing patients with other conditions, including those with diffuse parenchymal lung diseases and pulmonary arterial hypertension. Overall, it is an inexpensive test that can provide a wealth of data with potential impact on the treatment of several conditions. The test is self-paced, with standardized instructions and encouragement being given as patients walk as far as possible over 6 minutes through a flat corridor. The final distance is recorded in meters.

# Anatomy and Physiology

The interactions between the lungs and heart during exercise are the main physiological phenomena relevant to the test. In general terms, deoxygenated blood returning to the right heart via the venous circulation is pumped by the right ventricle into the pulmonary artery. As it advances through the pulmonary capillaries, gas exchange occurs when the capillaries meet the alveoli, with oxygen entering the circulation while carbon dioxide is released into the alveoli.

Oxygenated blood then circulates to the left heart, where the left ventricle pumps it to the systemic circulation, through which it is eventually delivered to the organs to sustain aerobic metabolism. The neurological and musculoskeletal systems are also involved in this process, particularly with concern to the process of matching minute ventilation to cardiac output in response to varying exercise intensity levels. This occurs via reflex responses that adjust the cardiac and pulmonary activity to the oxygen consumption levels required by the degree of exertion. Impairment of any of these components, the cardiac, pulmonary, neurological, or musculoskeletal systems, will decrease exercise tolerance.

# Indications

The 6MWT is primarily indicated for assessing the response to treatment in moderate-to-severe cardiac or pulmonary disease.

Other guideline-based indications for the 6MWT include its use to measure a patient's exercise tolerance and prognosis depending on the underlying condition.

Other conditions in which it can be helpful include idiopathic pulmonary fibrosis, cystic fibrosis, and sarcoidosis.

Functional impairment resulting from conditions affecting the neurological and muscular systems, such as fibromyalgia, Parkinson disease, multiple sclerosis, and spinal muscular atrophy, can also be reliably evaluated with the 6MWT.

# Contraindications

The only established absolute contraindication to the 6MWT is having a history of an acute coronary syndrome (either unstable angina or myocardial infarction) within 30 days prior to the test.

Relative contraindications include severe, uncontrolled hypertension and a resting heart rate greater than 120 beats per minute.

# Equipment

At a minimum, the equipment required for the test should include a pulse oximeter, a portable oxygen device (to be used if needed by the patient), a chair, a validated dyspnea scale (e.g., the Borg scale), and a stopwatch.

# Personnel

Medical personnel who must be knowledgeable in the standard protocol for the 6MWT conducts the test. A minimum requirement for staff conducting the six-minute walk test is training in Basic Life Support. Finally, the presence of a physician during the test may be requested at the discretion of the laboratory medical director or the prescribing physician.

# Preparation

The following are directives relevant to the preparation for the test, based on statements by the European Respiratory Society and American Thoracic Society

- Comfortable clothing, including walking shoes, should be worn.

- Patients should use any mobility aid device already needed to ambulate (e.g., a cane or walker).

- Patients should continue with their usual medications.

- Patients should rest for at least two hours before the test.

- Perform successive tests at the same time of the day to maintain consistency.

- Warm-ups are not allowed.

- Lung function tests should be done at least 15 minutes before the walk test if scheduled on the same day.

# Technique or Treatment

In general, the technician or other staff performing the test should observe the following steps

- The patient should rest for approximately 10 minutes before starting the test.

- Measure the baseline heart rate and oxygen saturation. These should be continuously monitored to identify the lowest oxygen saturation, which may occur before the end of the test.

- The patient's baseline dyspnea is then rated using the Borg scale.

- Set the lap counter and timer.

- Provide the patient with detailed instructions on how to proceed during the test.

- The patient is then positioned at the starting line and allowed to walk unassisted once the test begins.

- The technician should only address the patient during the test. As each minute passes, the patient should be informed of the time left to complete the test and encouraged to continue.

- At the end of the test, record the Borg dyspnea and fatigue levels, check heart rate and oxygen saturation, the number of laps from the counter or marks on the worksheet, and total distance walked.

# Complications

When standard protocols are followed, complications are rare. As noted previously, the self-paced character of the test limits their occurrence. The most common adverse event reported in the literature is oxygen desaturation below 80% resulting in termination of the test.

# Clinical Significance

The primary test outcome is the final distance walked (6MWD).

Factors associated with variability in test performance among healthy subjects include weight and age.

The 6MWT has limitations as a measure of exercise capacity that needs to be considered. Due to its nature, the study cannot identify the cause of dyspnea, or hypoxemia, or the mechanisms underlying a particular patient's exercise intolerance. Additionally, it cannot determine peak oxygen uptake, though it correlates with this cardiopulmonary exercise test measurement in select patients.

In the absence of specific clinical clues or an established diagnosis, a low 6MWD is a non-specific finding. In such situations, the cause of the abnormal finding should be investigated, with attention to the cardiac, pulmonary, or musculoskeletal systems, as guided by the patient's medical history.

The 6MWD has been established as a significant marker of disease severity for COPD patients since it directly correlates with lower quality of life indices, respiratory and functional impairment, and survival. It also reflects the clinical response to treatments such as lung volume reduction surgery. However, it does not have the same role for pharmacological interventions.

Other measures such as the body weight-walking distance product (D x W) have been proposed as alternative estimates of functional capacity in COPD patients. The DxW product correlates better with a patient's actual work of walking, as well as maximal oxygen uptake and anaerobic threshold, compared to walking distance alone.

In idiopathic pulmonary fibrosis, the 6MWD is also an independent predictor of mortality. A baseline 6MWD under 250 meters, and a subsequent decline greater than 50 meters in 24 weeks, are associated with a two- and three-fold increase in mortality, respectively.

As noted, the 6MWT has also been validated for use in cardiovascular diseases. In heart failure, a condition associated with functional disability and exercise intolerance, both in a sense analogous to the impairment of daily activity observed among COPD patients; the 6MWT can provide reliable data about physiological reserve and prognosis. In general, there is an inverse relation between NYHA class and 6MWD, with mean values of approximately 400, 320, and 225 meters for classes II, III, and IV, respectively. Decreased 6MWT performance is also associated with an increased risk of hospitalization and mortality.

The 6MWT also correlates with actual physical activity levels in patients with peripheral arterial disease, and it appears to be more so than treadmill testing.

In general terms, the minimal clinically important 6MWD change for patients with either cardiac or pulmonary disease is in the range of 14.0 to 30.5 meters.

While not affecting the organ systems involved in exercise directly, other conditions independently associated with a negative 6MWT performance in relation to the stage of the disease include chronic liver diseaseÂ and renal failure.

# Enhancing Healthcare Team Outcomes

Since test performance mainly reflects the integrated activity of the heart and lungs, information derived from the test will be relevant to assessing the degree of impairment associated with conditions affecting either or both of these organs. Therefore, pulmonologists and cardiologists will often be the clinicians requesting the 6MWT and using the data obtained. Other healthcare professionals that may use the 6MWT include primary care providers and anesthesiologists as part of preoperative risk assessments or in the general evaluation of patients with COPD.

Modified reference equations are available for use in offices with limited space.

Proper training of respiratory therapists, nurses, medical assistants, and other personnel conducting the test is an essential aspect of the procedure. Without their dedicated participation through its performance, the test may not be conducted reliably or safely. Accurate and timely notification to the ordering or supervising providers of test results or complications will improve patient outcomes and safety.